Tumour necrosis factor α: a potential target for the therapy of solid tumours

[1]  M. Mai,et al.  Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. , 2002, Cancer research.

[2]  M. Tisdale.  Cachexia in cancer patients , 2002, Nature Reviews Cancer.

[3]  R. Weichselbaum,et al.  Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. , 2002, The Lancet. Oncology.

[4]  G. Ramesh,et al.  TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity , 2002 .

[5]  S. J. Darnton,et al.  Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of action , 2002, Oncogene.

[6]  E. Matteson,et al.  Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. , 2002, Chest.

[7]  D. Phillips,et al.  Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway , 2002, Oncogene.

[8]  D. MacEwan.  TNF receptor subtype signalling: differences and cellular consequences. , 2002, Cellular signalling.

[9]  A. Tsimberidou,et al.  TNF-α targeted therapeutic approaches in patients with hematologic malignancies , 2002 .

[10]  D. Goeddel,et al.  TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.

[11]  M. Feldmann,et al.  Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.

[12]  P. Piguet,et al.  Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene , 2002, European Respiratory Journal.

[13]  F. Balkwill.  Tumor necrosis factor or tumor promoting factor? , 2002, Cytokine & growth factor reviews.

[14]  E. Ottaviani,et al.  Immunocytochemical Increased Evidence of Inducible Nitric Oxide Synthase, Tumor Necrosis Factor-&agr;, and Adrenocorticotropic Hormone in Human Peritumoral Lymph Nodes , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[15]  Jin Chen,et al.  Tumor Necrosis Factor-α Induction of Endothelial Ephrin A1 Expression Is Mediated by a p38 MAPK- and SAPK/JNK-dependent but Nuclear Factor-κB-independent Mechanism* , 2001, The Journal of Biological Chemistry.

[16]  H. Fujiki,et al.  A New Function of Green Tea: Prevention of Lifestyle‐related Diseases , 2001, Annals of the New York Academy of Sciences.

[17]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[18]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[19]  R. Dahiya,et al.  TUMOR NECROSIS FACTOR-α GENE MUTATIONS AND GENOTYPE CHANGES IN RENAL CELL CARCINOMA , 2001 .

[20]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB , 2001 .

[21]  N. Fausto,et al.  Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice , 2000, The Journal of experimental medicine.

[22]  F. Wiklund,et al.  Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  A. Körner,et al.  Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. , 2000, Cancer research.

[24]  A. Gotoh,et al.  TUMOR NECROSIS FACTOR-α REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINE , 2000 .

[25]  E Roman,et al.  High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  O. Tsitsilonis,et al.  Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice , 2000, European journal of immunology.

[27]  P. Carroll,et al.  FREQUENT GENOTYPE CHANGES AT −308, AND 488 REGIONS OF THE TUMOR NECROSIS FACTOR - α (TNF-α) GENE IN PATIENTS WITH PROSTATE CANCER , 2000 .

[28]  Jane Worthington,et al.  Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas , 2000, The British journal of dermatology.

[29]  C. Woodworth,et al.  Tumor necrosis factor‐α promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin‐dependent kinase activity in HPV‐immortalized keratinocytes by a ras‐dependent pathway , 2000, Molecular carcinogenesis.

[30]  M. Smyth,et al.  Tumor Necrosis Factor Sustains the Generalized Lymphoproliferative Disorder ( gld ) Phenotype , 2000, The Journal of experimental medicine.

[31]  L. Howells,et al.  Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex , 1999, Oncogene.

[32]  A. Filippini,et al.  Activation of Jun N-terminal Kinase/Stress-activated Protein Kinase Pathway by Tumor Necrosis Factor α Leads to Intercellular Adhesion Molecule-1 Expression* , 1999, The Journal of Biological Chemistry.

[33]  M. Marino,et al.  Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. , 1999, Cancer research.

[34]  R. Roberts,et al.  Cytokines in non-genotoxic hepatocarcinogenesis. , 1999, Carcinogenesis.

[35]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[36]  C. Rüegg,et al.  Clinical applications of TNF-α in cancer , 1998 .

[37]  F. Balkwill,et al.  Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). , 1998, British Journal of Cancer.

[38]  F. Locatelli,et al.  Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome , 1998, British journal of haematology.

[39]  S. Fox,et al.  Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. , 1998, British Journal of Cancer.

[40]  G. Salles,et al.  Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. , 1998, Blood.

[41]  T. Shono,et al.  Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis , 1997, Molecular and cellular biology.

[42]  G. Salles,et al.  Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  T. Colbert,et al.  TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. , 1995, Journal of immunology.

[44]  N. Watanabe,et al.  Endogenous tumor necrosis factor functions as a resistant factor against adriamycin , 1994, International journal of cancer.

[45]  Z. Qin,et al.  Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis , 1993, The Journal of experimental medicine.

[46]  A. Komori,et al.  Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. , 1993, Cancer research.

[47]  W. Foulkes,et al.  Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. , 1993, The Journal of clinical investigation.

[48]  J. Rüschoff,et al.  Enhancement of experimental metastasis by tumor necrosis factor , 1993, The Journal of experimental medicine.

[49]  Robert C. Bast,et al.  Tumor Necrosis Factor α as an Autocrine and Paracrine Growth Factor for Ovarian Cancer: Monokine Induction of Tumor Cell Proliferation and Tumor Necrosis Factor α Expression , 1993 .

[50]  F. Herrmann,et al.  Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Reiss,et al.  Tumor necrosis factor stimulates epithelial tumor cell motility. , 1991, Cancer research.

[52]  L. Bonewald,et al.  Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. , 1991, The Journal of clinical investigation.

[53]  G. Stamp,et al.  Investigation of cytokine gene expression in human colorectal cancer. , 1990, Cancer research.

[54]  R. Foà,et al.  Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. , 1990, Blood.

[55]  W. Fiers,et al.  Paradoxical effects of tumour necrosis factor in experimental ovarian cancer , 1989, International journal of cancer.

[56]  G. Wong,et al.  Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor , 1989, Cell.

[57]  P. Vassalli,et al.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis , 1989, The Journal of experimental medicine.

[58]  L. Moldawer,et al.  Anticachectin/tumor necrosis factor‐α antibodies attenuate development of cachexia in tumor models , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  G. Camussi,et al.  Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. , 1988, The Journal of biological chemistry.

[60]  W. Fiers,et al.  The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity , 1988, The Journal of experimental medicine.

[61]  A. Oliff,et al.  Tumors secreting human TNF/cachectin induce cachexia in mice , 1987, Cell.

[62]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.

[63]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. DuBois,et al.  Cyclooxygenase-2: a therapeutic target. , 2002, Annual review of medicine.

[65]  P. Richardson,et al.  Thalidomide: emerging role in cancer medicine. , 2002, Annual review of medicine.

[66]  G. Salles,et al.  Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. , 2001, The hematology journal : the official journal of the European Haematology Association.

[67]  G. Gores,et al.  Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. , 2000, Cancer research.

[68]  F. Balkwill,et al.  Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. , 1990, European journal of cancer.

[69]  H. Shepard,et al.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.

[70]  K. Takeda,et al.  Identity of differentiation inducing factor and tumour necrosis factor , 1986, Nature.